Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)

INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data available pertain to Asian populations in which such mutations are mo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: De Grève, Jacques, Van Meerbeeck, Jan, Vansteenkiste, Johan F., Decoster, Lore, Meert, Anne-Pascale, Vuylsteke, Peter, Focan, Christian, Canon, Jean-Luc, Humblet, Yves, Berchem, Guy, Colinet, Benoit, Galdermans, Danny, Bosquée, Lionel, Vermeij, Joanna, Dewaele, Alex, Geers, Caroline, Schallier, Denis, Teugels, Erik
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2016
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4816447/
https://ncbi.nlm.nih.gov/pubmed/27032107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0147599
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items